ECSP083351A - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
ECSP083351A
ECSP083351A EC2008003351A ECSP083351A ECSP083351A EC SP083351 A ECSP083351 A EC SP083351A EC 2008003351 A EC2008003351 A EC 2008003351A EC SP083351 A ECSP083351 A EC SP083351A EC SP083351 A ECSP083351 A EC SP083351A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
benzoyl
bioavailability
levels
compositions
Prior art date
Application number
EC2008003351A
Other languages
English (en)
Spanish (es)
Inventor
Graham Paul Matthews
Barbara Haberlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP083351(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP083351A publication Critical patent/ECSP083351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2008003351A 1999-02-16 2008-07-04 Composiciones farmacéuticas ECSP083351A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP083351A true ECSP083351A (es) 2008-08-29

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008003351A ECSP083351A (es) 1999-02-16 2008-07-04 Composiciones farmacéuticas

Country Status (34)

Country Link
US (3) US20020061873A1 (https=)
EP (1) EP1152750B1 (https=)
JP (2) JP5057610B2 (https=)
KR (2) KR100880859B1 (https=)
CN (1) CN100367930C (https=)
AR (2) AR022589A1 (https=)
AT (1) ATE430554T1 (https=)
AU (1) AU765776B2 (https=)
BR (1) BRPI0008228B8 (https=)
CA (1) CA2362277C (https=)
CL (1) CL2009001682A1 (https=)
CZ (1) CZ303979B6 (https=)
DE (1) DE60042151D1 (https=)
DK (1) DK1152750T3 (https=)
EC (1) ECSP083351A (https=)
ES (1) ES2326783T3 (https=)
GB (1) GB9903547D0 (https=)
HK (1) HK1045807B (https=)
HU (1) HUP0105364A3 (https=)
ID (1) ID30504A (https=)
IL (3) IL144512A0 (https=)
MY (1) MY128362A (https=)
NO (1) NO331232B1 (https=)
NZ (1) NZ513529A (https=)
PE (1) PE20001499A1 (https=)
PL (1) PL198330B1 (https=)
PT (1) PT1152750E (https=)
RU (1) RU2266121C2 (https=)
SI (1) SI1152750T1 (https=)
SK (1) SK286967B6 (https=)
TR (1) TR200102385T2 (https=)
TW (1) TWI240636B (https=)
WO (1) WO2000048571A1 (https=)
ZA (1) ZA200106677B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1372611B1 (en) * 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
PT1392313E (pt) 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
ES2269793T3 (es) 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
BR112012015433B8 (pt) * 2009-12-22 2020-03-03 Leo Pharma As composição farmacêutica substancialmente anidra para aplicação cutânea
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
KR20190032265A (ko) * 2015-12-09 2019-03-27 포스파제닉스 리미티드 약제학적 제형
CN114712308A (zh) 2015-12-09 2022-07-08 磷肌酸有限公司 药物制剂
EP3558903B1 (en) 2016-12-21 2024-07-03 Avecho Biotechnology Limited Process for phosphorylating a complex alcohol
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (https=) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP1142568A1 (en) * 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
AU692506B2 (en) 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
PE52896A1 (es) * 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733358A3 (de) * 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
AU4491697A (en) 1996-09-27 1998-04-17 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
EP1331002A3 (en) * 1997-01-30 2004-01-14 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin A
NZ502567A (en) 1997-07-29 2002-03-28 Upjohn Co Self-emulsifying formulation for lipophilic compounds containing a pyranone and a mixture of monoglycerides and diglycerides
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
KR20080064914A (ko) 2008-07-09
US8722664B2 (en) 2014-05-13
CN1339963A (zh) 2002-03-13
SI1152750T1 (sl) 2009-10-31
EP1152750A1 (en) 2001-11-14
ES2326783T3 (es) 2009-10-20
HUP0105364A2 (hu) 2002-05-29
SK11722001A3 (sk) 2001-12-03
DE60042151D1 (de) 2009-06-18
AU765776B2 (en) 2003-10-02
NZ513529A (en) 2003-10-31
HK1045807A1 (zh) 2002-12-13
MY128362A (en) 2007-01-31
CA2362277A1 (en) 2000-08-24
PT1152750E (pt) 2009-08-07
US20020061873A1 (en) 2002-05-23
TWI240636B (en) 2005-10-01
GB9903547D0 (en) 1999-04-07
HUP0105364A3 (en) 2003-02-28
US8575147B2 (en) 2013-11-05
KR20010093281A (ko) 2001-10-27
BRPI0008228B8 (pt) 2021-05-25
PE20001499A1 (es) 2001-01-12
JP5057610B2 (ja) 2012-10-24
CZ20012931A3 (cs) 2001-11-14
RU2266121C2 (ru) 2005-12-20
IL144512A0 (en) 2002-05-23
AR022589A1 (es) 2002-09-04
NO331232B1 (no) 2011-11-07
CA2362277C (en) 2010-03-30
NO20013964D0 (no) 2001-08-15
ATE430554T1 (de) 2009-05-15
AR082579A2 (es) 2012-12-19
ZA200106677B (en) 2003-01-14
JP2002537242A (ja) 2002-11-05
CL2009001682A1 (es) 2010-07-23
PL198330B1 (pl) 2008-06-30
EP1152750B1 (en) 2009-05-06
ID30504A (id) 2001-12-13
KR100880859B1 (ko) 2009-01-30
BRPI0008228B1 (pt) 2016-08-23
SK286967B6 (sk) 2009-08-06
IL192666A0 (en) 2009-02-11
US20140056974A1 (en) 2014-02-27
IL144512A (en) 2011-03-31
HK1045807B (zh) 2008-12-05
CZ303979B6 (cs) 2013-07-31
JP2012111763A (ja) 2012-06-14
NO20013964L (no) 2001-10-15
WO2000048571A1 (en) 2000-08-24
AU3154200A (en) 2000-09-04
CN100367930C (zh) 2008-02-13
TR200102385T2 (tr) 2002-09-23
DK1152750T3 (da) 2009-08-24
PL350556A1 (en) 2002-12-16
US20080070897A1 (en) 2008-03-20
BR0008228A (pt) 2001-10-30

Similar Documents

Publication Publication Date Title
ECSP083351A (es) Composiciones farmacéuticas
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
SE0001916D0 (sv) Novel formulation
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
MY141008A (en) Oral formulations of deoxypeganine and their uses
ECSP003551A (es) Complejo farmaceutico
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
ECSP003351A (es) Composiciones farmaceuticas
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AR027037A1 (es) Compusto y metodo para el tratamiento del dolor
DE10293092D2 (de) Schilddrüsentherapeutika